Alectinib, Entrectinib, Vemurafenib, Cobimetinib — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-11-30 in 4mo
ESTIMATED |
READOUT
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable
Phase 2 · Non-small Cell Lung Cancer |
Genentech, Inc. | Alectinib, Entrectinib, Vemurafenib, Cob |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|